Showing 4,501 - 4,520 results of 5,570 for search '"Oncology"', query time: 0.09s Refine Results
  1. 4501
  2. 4502
  3. 4503

    Evaluation of Prognostic Factors Following Flow-Cytometric DNA Analysis after Cytokeratin Labelling: II. Cervical and Endometrial Cancer by Pauline Wimberger, Peter Hillemanns, Thomas Kapsner, Hermann Hepp, Rainer Kimmig

    Published 2002-01-01
    “…In gynecologic oncology valid prognostic factors are necessary to define biologically similar subgroups for analysis of therapeutic efficacy. …”
    Get full text
    Article
  4. 4504
  5. 4505
  6. 4506
  7. 4507
  8. 4508

    Bioavailability study of enantiopure (S)-Equol in CD(SD)IGS rats by Seethakallu Ramachandraiah AnandaKumar, Mukund Handral, Srinivas Seekallu

    Published 2025-01-01
    “…Abstract The therapeutic potential of (S)-Equol across various health domains, including mental health and oncology has been identified and studied enormously. …”
    Get full text
    Article
  9. 4509
  10. 4510

    Activating Transcription Factor 5 Promotes Tumorigenic Capability in Cervical Cancer Through the Wnt/β-Catenin Signaling Pathway by Shi F, Wei Y, Huang Y, Yao D

    Published 2025-01-01
    “…Fengjuan Shi,1,2 Yumei Wei,2 Yingmei Huang,2 Desheng Yao1 1Department of Gynecologic Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People’s Republic of China; 2Department of Gynecology, the Fifth Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of ChinaCorrespondence: Desheng Yao, Email yaodesheng@gxmu.edu.cnPurpose: Cervical cancer is the fourth leading cause of cancer-related death in women. …”
    Get full text
    Article
  11. 4511
  12. 4512
  13. 4513
  14. 4514
  15. 4515
  16. 4516
  17. 4517
  18. 4518
  19. 4519
  20. 4520

    A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma by Margaret Hux, Denise Zou, Esprit Ma, Peter Sajosi, Andreas Engstrom, Ross Selby, Eugene Benson, Andrew Briggs, Vijayveer Bonthapally

    Published 2016-10-01
    “…Conversely, considering only patients with Eastern Corporative Oncology Group performance status of 0 or 1 increased the ICER to approximately £38 200. …”
    Get full text
    Article